港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

生物醫藥B類股

430.463

+8.7162.07%

漲家數：27

跌家數：4

平家數：3

市盈率：- -

高：431.911

開：421.747

低：421.747

收：421.747

資料載入中...

總覽新聞資訊

【基石藥業-B(02616.HK)在澳大利亞遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤的臨牀試驗申請】基石藥業-B(02616.HK)發佈公告，公司已在澳大利亞成功遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤(DLBCL)的Ib期臨牀試驗申請。此外 CS5001單藥及聯合PD-L1單抗治療晚期實體瘤的全球多中心臨牀試驗也在同步開展。

基石藥業-B(02616)在澳大利亞遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤的臨牀試驗申請

和鉑醫藥-B(02142.HK)：收到與WINDWARD BIO AG關於HBM9378/SKB378授權協議的首付款

亞盛醫藥-B(06855)：耐立克®治療費城染色體陽性(Ph+)急性淋巴細胞白血病獲突破性療法認定

智通财经网

西藏海思科製藥有限公司申請I類會議

【歐股“十一羅漢”｜諾和諾德收漲約2.5%，阿斯麥漲超1.8%，雀巢則跌超1.8%】週三，阿斯麥控股荷蘭阿姆斯特丹股價收漲1.85%，報672.70歐元。諾和諾德哥本哈根股價收漲2.48%，報631.50。德國思愛普Sap收漲2.22%，歐萊雅漲1.79%，諾華製藥漲0.62%。阿斯利康、羅氏製藥、LVMH集團、賽諾菲則收跌0.02%-0.46%，葛蘭素史克跌1.72%，雀巢跌1.83%。

恩華藥業(002262.SZ)擬出資350萬美元認購三晟醫藥Pre-A輪優先股1250萬股

恩華藥業：擬出資350萬美元購買三晟醫藥Pre-A輪優先股1250萬股

视频滚动新闻

授權合作獲益、尚無產品上市，和譽醫藥首度實現全年盈利

華東醫藥(000963.SZ)：三類醫療器械光學射頻治療儀V30註冊申請獲得受理

科創板第五套標準激發創新藥企活力助力中國生物醫藥企業加速崛起

经济参考网

星昊醫藥收盤上漲1.62%，滾動市盈率19.97倍，總市值19.97億元

國家醫保局：國家醫保信息平台累計歸集追溯碼227億條

沛嘉醫療(09996.HK)Trilogy經導管心臟瓣膜系統於台灣完成首兩宗植入

阿斯达克财经

沛嘉醫療-B(09996)：TrilogyTM經導管心臟瓣膜系統於中國臺灣的首兩例植入成功完成

CAR-T的“資本寒冰”開始融化

Ofweek维科网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":430.4633,"timestamp":1741248510375,"preClose":421.74713,"halted":0,"volume":196751826,"delay":0,"changeRate":0.020667,"change":8.716156,"pbRate":3.352817,"amount":2078205803,"amplitude":0.024099,"prevYearClose":331.1933,"fiveDayClose":431.446,"twentyDayClose":333.662,"turnoverRate":0.00762,"marketCap":241153069920,"floatMarketCap":226975358368,"peRate":-16.712341},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":431.91098,"amplitude":0.024099,"preClose":421.74713,"low":421.74713,"pbRate":"3.352817","latestPrice":430.4633,"volume":196751826,"delay":0,"open":421.74713,"prevYearClose":331.1933,"prevWeekClose":411.011,"prevMonthClose":411.011,"prevQuarterClose":331.193,"fiveDayClose":431.446,"twentyDayClose":333.662,"sixtyDayClose":346.493,"secType":"PLATE","market":"HK","turnoverRate":0.00762,"peRate":-16.712341,"marketCap":241153069920,"floatMarketCap":226975358368,"timestamp":1741248510375,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":27,"down":4,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:16,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517497936","title":"【基石藥業-B(02616.HK)在澳大利亞遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤的臨牀試驗申請】基石藥業-B(02616.HK)發佈公告，公司已在澳大利亞成功遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤(DLBCL)的Ib期臨牀試驗申請。此外 CS5001單藥及聯合PD-L1單抗治療晚期實體瘤的全球多中心臨牀試驗也在同步開展。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517497936","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517497936?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 08:13","pubTimestamp":1741220034,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06081348552983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","ADC","BK1161","03347","BK4080","BK1141","02616","BK1583","BK4023","BK4231","BK1576","LU1169590202.USD","PD","LU1169589451.USD"],"gpt_icon":0},{"id":"2517763909","title":"基石藥業-B(02616)在澳大利亞遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤的臨牀試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2517763909","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517763909?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 08:07","pubTimestamp":1741219667,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司已在澳大利亚成功递交CS5001联合标准治疗用于一线弥漫大B细胞淋巴瘤的Ib期临床试验申请。CS5001用于治疗多种实体瘤的全球多中心Ib期临床试验正在同步开展中。本次Ib期临床试验在CS5001单药治疗后线侵袭性和惰性晚期淋巴瘤的数据基础上进一步拓展，旨在深入探索ROR1 ADC在DLBCL全病程的临床应用价值，并持续拓展实体瘤治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","03347","BK1141","BK1574","BK1576","BK1583","BK4080","BK4231","ADC","BK1161"],"gpt_icon":0},{"id":"2517397662","title":"和鉑醫藥-B(02142.HK)：收到與WINDWARD BIO AG關於HBM9378/SKB378授權協議的首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2517397662","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517397662?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 08:07","pubTimestamp":1741219650,"startTime":"0","endTime":"0","summary":"格隆汇3月6日丨和铂医药-B(02142.HK)发布公告，公司及科伦博泰生物-B(06990.HK)作为授权方与Windward Bio AG (“Windward Bio”)作为获授权方就HBM9378/SKB378订立独家授权协议。公司已根据协议收到相应首付款，包括现金付款及Windward Bio母公司的股权。该首付款的到账将进一步充盈公司的现金储备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/06080748552971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK4210","BK4121","BK4588","LU1169589451.USD","02142","LU1169590202.USD","BK1574","BK1583","BK4585","AG","BIO"],"gpt_icon":0},{"id":"2517997516","title":"亞盛醫藥-B(06855)：耐立克®治療費城染色體陽性(Ph+)急性淋巴細胞白血病獲突破性療法認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2517997516","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517997516?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 07:55","pubTimestamp":1741218920,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司原创1类新药奥雷巴替尼获国家药品监督管理局药品审评中心纳入“突破性治疗品种”名单，用于联合化疗一线治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者。这是耐立克第三次获CDE纳入突破性治疗品种。2023年7月，耐立克获CDE临床试验许可，开展其联合化疗对比伊马替尼联合化疗治疗新诊断Ph+ ALL患者的全球注册III期临床研究，意味着该药物有望成为国内首个获批用于一线治疗Ph+ ALL的TKI药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"亚盛医药-B(06855)：耐立克®治疗费城染色体阳性(Ph+)急性淋巴细胞白血病获突破性疗法认定","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","06855","AAPG","BK4139","BK1574"],"gpt_icon":0},{"id":"2517920838","title":"西藏海思科製藥有限公司申請I類會議","url":"https://stock-news.laohu8.com/highlight/detail?id=2517920838","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517920838?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 06:18","pubTimestamp":1741213083,"startTime":"0","endTime":"0","summary":"西藏海思科制药有限公司，成立于2019年，位于山南市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，西藏海思科制药有限公司共对外投资了1家企业，参与招投标项目6次，知识产权方面有商标信息33条，专利信息175条，此外企业还拥有行政许可2个。主要股东信息显示，西藏海思科制药有限公司由海思科医药集团股份有限公司持股100%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/06061848551492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK1191","BK0077","BK1574","BK0033","002653","BK0188","01477","BK0028"],"gpt_icon":0},{"id":"2517477049","title":"【歐股“十一羅漢”｜諾和諾德收漲約2.5%，阿斯麥漲超1.8%，雀巢則跌超1.8%】 週三，阿斯麥控股荷蘭阿姆斯特丹股價收漲1.85%，報672.70歐元。諾和諾德哥本哈根股價收漲2.48%，報631.50。德國思愛普Sap收漲2.22%，歐萊雅漲1.79%，諾華製藥漲0.62%。阿斯利康、羅氏製藥、LVMH集團、賽諾菲則收跌0.02%-0.46%，葛蘭素史克跌1.72%，雀巢跌1.83%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517477049","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517477049?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 01:53","pubTimestamp":1741197233,"startTime":"0","endTime":"0","summary":"周三，阿斯麦控股荷兰阿姆斯特丹股价收涨1.85%，报672.70欧元。诺和诺德哥本哈根股价收涨2.48%，报631.50。德国思爱普Sap收涨2.22%，欧莱雅涨1.79%，诺华制药涨0.62%。阿斯利康、罗氏制药、LVMH集团、赛诺菲则收跌0.02%-0.46%，葛兰素史克跌1.72%，雀巢跌1.83%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06015348550800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00BJJMRZ35.SGD","LU1734074674.USD","IE00BD6J9T35.USD","LU2417539215.USD","BK4578","LU0345774631.USD","IE00BJT1NW94.SGD","LU0823434583.USD","BK4585","BK4588","LU0211331839.USD","IE0009355771.USD","AZN","BK4212","LU0345774391.USD","LU0889565916.HKD","GSK","IE0002141913.USD","IE00B2B36J28.USD","LRLCY","LU1093756168.USD","03165","LU0823434740.USD","LU2456880835.USD","BK4147","IE00B4R5TH58.HKD","IE00BZ1G4Q59.USD","GSK.UK","IE00BFTCPJ56.SGD","BK4543","BK1574","NVS","LU0154236417.USD","IE0004445239.USD","LU1093756325.SGD","LU0097036916.USD","LU2462157665.USD","NSRGY","LU0109394709.USD","NVO","BK4532","LU0320765992.SGD","01477","BK4599","BK4007","IE00BKVL7J92.USD","BK1191","BK4568","LU2236285917.USD","ASML"],"gpt_icon":0},{"id":"2517913923","title":"恩華藥業(002262.SZ)擬出資350萬美元認購三晟醫藥Pre-A輪優先股1250萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2517913923","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517913923?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 19:58","pubTimestamp":1741175893,"startTime":"0","endTime":"0","summary":"本次认购三晟医药Pre-A轮优先股的定价依据系基于公司对三晟医药的在研产品储备、研发实力、未来的发展潜力以及与三晟医药及其子公司未来在产品授权研发及市场化方面的深度合作，在咨询专业机构后，经各方协商一致确认。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1161","002262","159938","BK0188","BK1574","BK1515","BK0070","09939"],"gpt_icon":0},{"id":"2517158009","title":"恩華藥業：擬出資350萬美元購買三晟醫藥Pre-A輪優先股1250萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2517158009","media":"视频滚动新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517158009?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 19:52","pubTimestamp":1741175520,"startTime":"0","endTime":"0","summary":"恩华药业公告，公司拟出资350万美元购买三晟医药的Pre-A轮优先股1250万股，交易完成后公司将持有三晟医药10.448%的股权。三晟医药是一家专注于发现和开发治疗中枢神经系统疾病的创新药物的生物科技公司。此次投资旨在加快创新药物的研发及引进工作，提升公司药物研发效率及市场竞争力，获取新的利润增长点。交易完成后，三晟医药将成为公司的参股公司。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/videoroll/2025-03-05/doc-inenrcyf7623869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","002262","BK0188","159938","09939","BK0070","BK1574","BK1515","BK0239"],"gpt_icon":0},{"id":"2517543913","title":"授權合作獲益、尚無產品上市，和譽醫藥首度實現全年盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2517543913","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517543913?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 19:33","pubTimestamp":1741174410,"startTime":"0","endTime":"0","summary":"和誉医药近日披露2024年业绩，报告期内实现营收5.04亿元，凭借授权款和里程碑付款，尚无产品上市的和誉医药首度实现全年盈利，年内利润为2830.2万元。和誉医药表示，目前有充裕的在手现金储备，现金及银行结余约19.59亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503053337413564.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503053337413564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","BK1515","02256","09939","BK1574","BK1161"],"gpt_icon":0},{"id":"2517499730","title":"華東醫藥(000963.SZ)：三類醫療器械光學射頻治療儀V30註冊申請獲得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2517499730","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517499730?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 18:52","pubTimestamp":1741171927,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华东医药 发布公告，2025年3月5日，公司全资子公司Viora Ltd.收到国家药品监督管理局签发的《受理通知书》，其申报的三类医疗器械光学射频治疗仪V30注册申请获得受理。V系列产品兼容性强，可适配未来Viora开发的新技术。V30已获得美国FDA、欧盟 CE注册认证。本次V30顺利完成注册受理，是其在中国注册进程中的又一个重大里程碑，公司后续将继续积极推进这款产品在中国的注册工作，推动其早日在国内上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09997","LU2328871848.SGD","BK0187","BK0209","BK0183","LU1969619763.USD","159883","BK0175","BK1222","BK1583","BK1574","BK1100","000963","BK0188","BK0132","09996","BK0196"],"gpt_icon":0},{"id":"2517982994","title":"科創板第五套標準激發創新藥企活力 助力中國生物醫藥企業加速崛起","url":"https://stock-news.laohu8.com/highlight/detail?id=2517982994","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517982994?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 17:58","pubTimestamp":1741168684,"startTime":"0","endTime":"0","summary":"近期，证监会主席吴清在《充分发挥资本市场功能更好服务新型工业化》文章中表示，要深入研究完善发行上市、私募创投等制度安排，增强资本市场制度竞争力，提升对新产业新业态新技术的包容性和适配性。科创板作为资本市场改革“试验田”，持续推动一系列创新制度在科创板先行先试、落地生根，成功助力一批科技创新企业加速关键核心技术突破、加快实现高质量发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503053337354133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2517912199","title":"星昊醫藥收盤上漲1.62%，滾動市盈率19.97倍，總市值19.97億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517912199","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517912199?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 17:56","pubTimestamp":1741168562,"startTime":"0","endTime":"0","summary":"3月5日，星昊医药今日收盘16.33元，上涨1.62%，滚动市盈率PE达到19.97倍，创56天以来新低，总市值19.97亿元。从行业市盈率排名来看，公司所处的化学制药行业市盈率平均45.51倍，行业中值26.30倍，星昊医药排名第69位。资金流向方面，3月5日，星昊医药主力资金净流入139.66万元，近5日总体呈流入状态，5日共流入1042.52万元。最新一期业绩显示，2024年三季报，公司实现营业收入4.68亿元，同比-9.91%；净利润7877.01万元，同比8.22%，销售毛利率69.38%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/05175648542748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159938","BK1515","BK1161","BK1574","09939"],"gpt_icon":0},{"id":"2517999931","title":"國家醫保局：國家醫保信息平台累計歸集追溯碼227億條","url":"https://stock-news.laohu8.com/highlight/detail?id=2517999931","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517999931?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 17:37","pubTimestamp":1741167430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1515","BK1161","BK1574","09939","159938"],"gpt_icon":0},{"id":"2517980009","title":"沛嘉醫療(09996.HK)Trilogy經導管心臟瓣膜系統於台灣完成首兩宗植入","url":"https://stock-news.laohu8.com/highlight/detail?id=2517980009","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517980009?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 16:56","pubTimestamp":1741164960,"startTime":"0","endTime":"0","summary":"沛嘉医疗(09996.HK) 宣布，用于治疗重度主动脉瓣反流的Trilogy经导管心脏瓣膜系统，已于台湾完成首两例植入。(gc/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-05 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200911173949451_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200911173949451_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422380/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["159891","BK1574","BK1100","09996","BK1583"],"gpt_icon":0},{"id":"2517725998","title":"沛嘉醫療-B(09996)：TrilogyTM經導管心臟瓣膜系統於中國臺灣的首兩例植入成功完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2517725998","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517725998?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 16:55","pubTimestamp":1741164936,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沛嘉医疗-B(09996)公布，用于治疗重度主动脉瓣反流的 TrilogyTM经导管心脏瓣膜(THV)系统于中国台湾的首两例植入成功完成。TrilogyTM THV系统为拥有独占许可并获得CE标志认证的经导管主动脉瓣置换产品，适用于心脏团队(包括心脏外科医生)判定为外科主动脉瓣置换手术风险高或较高的症状性重度主动脉瓣反流或症状性重度主动脉瓣狭窄患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1100","BK1583","159891","09996"],"gpt_icon":0},{"id":"2517960367","title":"CAR-T的“資本寒冰”開始融化","url":"https://stock-news.laohu8.com/highlight/detail?id=2517960367","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517960367?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 16:22","pubTimestamp":1741162931,"startTime":"0","endTime":"0","summary":"在市场情绪最低落的时候，事情却悄然发生转机，艺妙神州、科济药业纷纷在近期宣布完成CAR-T融资协议，禁锢CAR-T产业的“寒冰”正在开始融化。这一融资金额虽然并不够，但考虑到通用型CAR-T依然处于临床早期阶段，表明资本已经开始将通用型CAR-T纳入估值体系。国内特殊的支付环境是CAR-T发展的最大障碍。科济药业与珠海软银的此次合作，或将成为CAR-T“资本寒冰”溶解的标志性事件。此外，CAR-T治疗实体瘤失败的案例更是频发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305162228963a6e0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305162228963a6e0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1585","BK1161","BK1574","BK1587","02171"],"gpt_icon":0}],"pageSize":16,"totalPage":43,"pageCount":6,"totalSize":677}]}}